Activator protein -1 ( AP -1 ) transcription factor has been linked to chemotherapeutic resistance. To assess the clinical efficacy of AP -1 inhibition toward reversing drug resistance, we have developed an adenovirus expressing a dominant negative that inhibits AP -1 DNA binding, named AdA -FOS. We examined the consequence of AdA -FOS infection on two paired human cancer cell lines, each pair consisting of a parental cell and the drug -resistant derivative. The first pair of cells is the parental human ovarian cancer cell line A2780 and the cisplatin -resistant A2780 / CP70 cell line. The second pair of cells is the parental epidermal carcinoma cell line KB8 and the multidrug -resistant ( mdr ) KB85 cell line. Because of an association of up -regulated AP -1 activity with their drug resistance, these cell lines were considered good targets of AdA -FOS therapy. Following infection of the drug -sensitive and drug -resistant cells, we observed a significant decrease in cell viability of KB85 and A2780 / CP70 cells at drug doses normally not lethal to the cell. The parental cell lines, A2780 and KB8 cells, were not similarly affected by AdA -FOS. This decrease in viability was specific to AdA -FOS as an adenovirus control ( Advector ) did not reverse drug resistance. Although the efficiency of AdA -FOS in therapy would need to be further analyzed with other cisplatin -resistant and mdr cell lines, these results suggest that AP -1 is a therapeutic molecular target and that inhibition of AP -1 DNA binding may be of clinical value in treating chemotherapeutic resistance.
A ctivating protein -1 ( AP -1) is a family of transcription factors composed of heterodimers of a JUN family member and a FOS family member that bind the 5 0 -TGAGTCA -3 0 DNA sequence called TRE ( 12-O -tetradecanoylphorbol -13-acetate response element ).
1 -3 AP -1 DNA -binding activity has been implicated in a wide variety of cellular functions. These include cell growth, 4, 5 apoptosis, 6 cell differentiation, 7 RAS -mediated transformation, 8 -11 and a variety of stress responses. The AP -1 complex has also been implicated in chemotherapeutic drug resistance in a variety of cell lines. 12 -14 One of the major obstacles in the clinical efficacy of chemotherapeutic cytotoxicity is the development of drug resistance. 15 -19 To study the importance of AP -1 in mediating drug resistance and to overcome AP -1 -mediated drug resistance, we have generated an adenovirus termed AdA -FOS that expresses A -FOS, a dominant negative ( DN ) that abolishes AP -1 DNA binding. A -FOS belongs to a class of DNs to B -ZIP transcription factors, termed AZIPs, that function by high -affinity dimerization with the endogenous B -ZIP proteins. 9,20 -23 A -FOS consists of the FOS leucine zipper dimerization domain and a designed 25 amino acid acidic amphipathic sequence that replaces the basic region. The A -FOS acidic domain interacts with the JUN basic DNA -binding region. The interaction between the acidic and basic regions serves the dual function of stabilizing the A -FOS / JUN heterodimeric complex by 4.6 kcal /mol and preventing the complex from binding DNA.
We used two pairs of cancer cell lines to examine the effect of AdA -FOS on drug resistance; in each case the drug -resistant cell line was derived from the parental cell. The first pair of cells is the human ovarian cancer cell line A2780 and the cisplatin -resistant derivative A2780 / CP70. 24 A2780 /CP70 cells are 10 -fold more resistant to cisplatin than A2780. 25 Cisplatin [cis -diamminedichloroplatinum ( II )] is an effective chemotherapeutic agent widely used to treat human ovarian, bladder, testicular, lung, and intestinal cancers. 26, 27 The molecular basis of cellular resistance to cisplatin is complex. Mechanisms of resistance include enhanced DNA repair of platinum -DNA adducts, 28 -30 impaired uptake of cisplatin, 25 enhanced intracellular detoxification by glutathione systems, 31 and ablation of p53-mediated apoptosis. 32 Cisplatin resistance in A2780 /CP70 cells is accompanied by an increase in AP -1 DNA -binding activity and ERCC1 mRNA concentration. The ERCC1 gene has an AP -1 site in its promoter that has been implicated in the increased cisplatin resistance in the cisplatin-resistant A2780 /CP70 cells. 30 The second pair of cells was derived from KB -3-1, a HeLa subline. 33 KB8 was isolated as a first -step isolate in colchicine from KB -3 -1. This cell line exhibits a 2 -fold increase in resistance to colchicine and is slightly cross -resistant to adriamycin and puromycin. KB85 is a second -step isolate that has four times the resistance to colchicine and is cross -resistant to adriamycin, vinblastine, actinomycin D, and vincristine, which characterizes the full multidrug -resistant phenotype (mdr ). A factor in the development of mdr is overexpression of p -glycoprotein (p-gp).
19 P -gp is an energy-dependent transmembrane efflux pump that transports unrelated cytotoxic drugs from the cell. 34, 35 P -gp is encoded by the mdr-1 gene, which is associated with several drug -resistant cancers and is highly expressed in KB85 cells. 36 -38 KB cells selected for mdr contain elevated c -jun and c-fos mRNA expression and an AP -1 site has been identified in the murine and human mdr1 gene promoter. 39, 40 We examined whether AdA -FOS could be used in combination with chemotherapeutic treatment to lead to selective killing of the two derived drug -resistant cell lines but not the parental cells. AdA -FOS reversed drug resistance in A2780 /CP70 and KB85 cells and did not affect the parental A2780 and KB8 cells. The selectivity of AdA -FOS was demonstrated by comparing its activity against five additional adenoviruses. AdA -FOS alone inhibited cisplatin resistance in A2780/CP70 cells. Furthermore, cell growth in the absence of cisplatin was inhibited by AdA -FOS. We were able to demonstrate that the AP -1 DNA binding of A2780/ CP70 and KB85 cells was inhibited upon infection with AdA -FOS. Therefore, AP -1 can be considered a potential therapeutic target for reversing chemoresistance of cancer cells.
Methods

Generation of recombinant adenovirus
Advector, our empty vector control, is a modification of pACCMV.pLpA 41 by insertion of the following oligo: 5 0 -AAT TCC ACC ATG GAC TAC AAG GAC GAC GAT GAC AAG CAT ATG TGA TGA -3 0 and the appropriate second strand, into the EcoRI and HindIII site. Insertion of the oligo replaced the original cloning site with the following sites EcoRI, NcoI, NdeI, and HindIII, and FLAG epitope between the NcoI and NdeI restriction sites. The A -ZIP or A -HLH -ZIP DNs were cloned into Advector as a NdeIHindIII DNA fragment. Plasmids were sent to BioReliance (Rockville, MD) where double -banded cesium chloride viral stocks dialyzed into 10 mM TRIS, 2 mM MgCl 2 , and 10% glycerol were generated.
Cells
A2780 and A2780 /CP70 cells 24 were grown in RPMI, 10% fetal calf serum, 2 mM glutamine, 0.2 U /mL human insulin, 50 U penicillin, 50 g /mL streptomycin in 378C, and 7% CO 2 . KB85 and KB8 cells 33 were grown in DMEM, 10% fetal calf serum, 2 mM glutamine and 50 U penicillin in 378C and 7% CO 2 .
PCR analysis of dominant negative inserts
Recombinant adenoviruses ( 1Â10 7 ) were used to infect a confluent 10 -cm plate of 293 cells for 2 days and cellular lysate was collected. This lysate was collected by centrifugation and viral DNA was isolated from the supernatant by precipitation in 0.3 M NaCl and 35% isopropanol followed by phenol /chloroform extraction and ethanol precipitation. Insert DNA was amplified by PCR using these oligos, 5
0 -CGG TGG GAG GTC TAT ATA AGC AGA -3 0 and 5 0 -GTC ACA CCA CAG AAG TAA GGT-3 0 , and analyzed on a 3% agarose gel. DNA fragments were isolated from the gel and sequenced.
Particles: pfu
Viral stocks were titered on 293 cells to determine plaqueforming units (pfu ). Particle numbers were determined by OD measurement at 260 nm. The adenoviruses had the following particle number /pfu ratios. AdA -C /EBP 143:1, AdA -FOS 187:1, AdA -FOS( HA ) 140:1, AdA -VBP 125:1, AdA -MAX 38:1, AdA -USF 158:1, AdA -MI 100:1, Advector 110:1.
Adenoviral infections
Adenovirus infections were performed in growth medium. A total of 1250 cells per well were plated in a 96 -well plate and after 24 hours the cells were infected with 1250 infectious particles in 100 L resulting in an MOI of 1. This concentration of adenovirus was used in all experiments to define an MOI of 1 independent of cell density. The appropriate MOI to use in each experimental procedure was determined by independent dose -response curves performed for each cell line ( Fig 2C and D ) . Typically, the Cancer Gene Therapy KB8, KB85, and A2780/CP70 cells were infected at an MOI of 10 and A2780 cells were infected at an MOI of 500. The exception to this is Western analysis of the A2780 /CP70 cells in which we examined levels of protein expression following 2 days of infection with an MOI of 100. Colchicine was added at doses of 1, 3, 10, 30, and 100 ng/ mL. TACS 2 MTT assay ( Trevigen, Gaithersburg, MD ) was performed 48 hours later according to the manufacturers instructions. IC 10 cisplatin doses were 1 and 0.1 m for A2780/ CP70 cells and A2780 cells, respectively. Colchicine IC 10 doses were 10 and 3 ng/ mL for KB8 and KB85 cells, respectively. Drug and viral dose responses were determined after 6 days of either infection alone or drug treatment alone by MTT.
Western analysis
A2780 /CP70 in a six -well plate were infected with Advector, AdA -ZIPs, and AdA -HLH -ZIPs for 2 days at an MOI of 100. Cells were collected by scraping and centrifugation and lysed by freeze /thaw and incubation in Figure 2 Drug and Advector killing of A2780 and A2780 / CP70 human ovarian cancer cells and KB8 and KB85 epidermal carcinoma cells. A: The dose response of A2780 and A2780 / CP70 cells to cisplatin was assayed by the MTT assay. Viability was assayed 6 days after infection. Cellular growth ( MTT ) was determined by measuring absorbance at 595 nm. B: As described above, the dose response of KB8 and KB85 cells to colchicine was assayed by MTT. C and D: Cell killing by Advector for all four cell lines was determined by infecting cells with increasing doses of Advector and assaying by MTT 6 days after infection. Time points for viral killing reflect experimental conditions for drug and adenovirus experiments. Cancer Gene Therapy RIPA buffer ( 50 mM Tris pH 7.5, 1% NP40, 150 mM NaCl, 4 mM EDTA, 1 mM aprotinin, 1 mM PMSF, 1 mM leupeptin, 1 mM pepstatin, and 1 mM DTT ). Thirty micrograms of protein was loaded and separated on a 16% PAGE stacking gel. Proteins were transferred to 0.22-m nitrocellulose. Membrane was prehybridized in 5% ovalbumin, 1% dry milk, and 1 M glycine and washed in wash solution [1Â PBS with 0.1% ovalbumin, 0.1% dry milk and 0.1% Tween 20 ( vol /vol ) ]. Anti -FLAG ( Sigma, Woodland, TX ) or anti -HA ( Boehringer Mannheim, Indianapolis, IN ) was diluted 1:1000 and incubated with the blot membrane followed by anti -mouse Ig horseradish peroxidase conjugate (Amersham, Piscataway, NJ ) diluted to 1:3000. FLAG or HAlinked proteins were visualized using chemiluminescence.
Immunohistochemistry
Cells were plated in 1 -mL slide flasks (Nunc, Naperville, IL ) and infected for 4 days. Each cell type was infected at the IC 50 adenoviral dose ( Fig 2 ) . A2780 was infected with an MOI of 500 whereas an MOI of 10 was used for CP70, KB8, and KB85 cells. Cells were fixed with 4% paraformaldehyde in PBS for 20 minutes at room temperature and then in 100% methanol for 10 minutes. After blocking with 3% bovine serum albumin and 0.1% Tween 20 in PBS, slides were incubated in 1:1000 dilution of M2 FLAG antibody in blocking buffer for 2 hours. Following this, cells were incubated for 1 hour with fluorescein isothiocyanateconjugated rat anti -mouse antibody used at a 1:100 dilution in blocking buffer. Cells were washed in PBS with 0.05% Tween 20 twice for 10 minutes following each incubation with antibody. Nuclei were stained with Hoescht 33342 followed by a wash in PBS with 0.05% Tween 20 and then PBS. Images were visualized with green and blue filters using a confocal laser scanning microscope ( Zeiss, Thornwood, NJ).
Colony -formation assay
To determine the inhibitory concentration by 10% (IC 10 ) and 50% (IC 50 ) of chronic cisplatin treatment, increasing doses of cisplatin were added to the cells. Six days after cisplatin treatment, cells were stained with crystal violet and counted. We determined that the IC 10 50 . To analyze the effect of cisplatin and adenoviral treatment combinations, cells were infected at an MOI of 10 for 2 days before the addition of the IC 10 cisplatin dose. Six days after cisplatin treatment, cells were stained with crystal violet and counted. Colony formation is presented as percent growth when compared to uninfected cells. EMSA A2780/ CP70 or KB85 cells, in a 10 -cm plate, were infected with vector and AdA -FOS at an MOI of 10. After 96 hours, 1 M cisplatin was added to the A2780 /CP70 cells and 10 ng /mL colchicine was added to the KB85 cells for 18 hours and nuclear proteins were isolated. 9 Ten micrograms of nuclear protein was incubated with 8 pg of radiolabeled AP -1 probe in a buffer containing 10 mM Hepes pH 7.8, 4 mM Tris, 50 mM KCl, 1 mM EDTA, 1 mM DTT, and 10% glycerol for 10 minutes at room temperature. Binding complexes were resolved on an 8% polyacrylamide gel in 0.25% TBE buffer at room temperature. The sequence of the AP -1 probe is 5 0 -GTCAGTCAGTGACTCAATCGGTCA -3 0 ; the TRE is shown in bold.
Results
Construction of adenovirus expressing dominant negatives to B -ZIP or B -HLH -ZIP transcription factors
Advector, our empty vector control, is a modification of pACCMV, 41 which is a first -generation (ÁE1 and ÁE3 ) adenovirus with a CMV promoter. Modifications include an insert with an N -terminal epitope (FLAG or HA ) and an NdeI and HindIII cloning sites for the insertion of A -ZIP or A -HLH -ZIP DNs in frame. Three A -ZIPs, A -C /EBP, 21 A -FOS, 9 and A -VBP 22 and three A -HLH -ZIP's, A -USF, 42 A -MAX, and A -MI, 43 were inserted into Advector 41, 44 (Fig 1) . The ratio of optical activity to plaque -forming units (pfu ) indicated that the stocks contain on average one infectious unit for every 100 particles ( see Methods ).
A cell line -specific effect on cell viability of A2780, A2780 / CP70 cells, KB8, and KB85 cells
An MTT cell growth assay was used to examine cell viability after drug addition of cisplatin (A2780 and A2780 /CP70 ), colchicine (KB8 and KB85 ) or Advector. We determined the concentration of cisplatin necessary to inhibit cell growth of A2780 and A2780 /CP70 cells by 10% (IC 10 ) to be 0.1 and 1 m, respectively (Fig 2A ) . The IC 10 of colchicine on KB8 and KB85 cells was 3 and 10 ng/ mL, respectively ( Fig 2B ) .
A cell line -specific sensitivity to adenoviral -mediated cytotoxicity was observed. A2780/ CP70 cells were sensitive to a 50-fold lower viral dose than the parental A2780 cells ( Fig 2C ) . In contrast, similar levels of Advector were cytotoxic in both of the KB cell lines. The appropriate MOI to use in each experimental procedure was determined by these independent dose -response curves (Fig 2C and D ) . We analyzed the relative level of expression of A -FOS in each cell line infected with an MOI of 10 for KB8, KB85, and A2780/ CP70 or an MOI of 500 for A2780 by immunohistochemistry (Fig 3 ) . Immunofluoresence with a FLAG antibody indicates that the A -ZIPs are expressed in 100% of the cells and in equivalent levels in each cell line. Another observation is that A -FOS is distributed throughout the cytoplasm and nucleus.
Drug -resistant A2780 / CP70 cells and KB85 cells exhibit a selective inhibition of growth by AdA -FOS
To study the importance of AP -1 activity in mediating drug resistance and to overcome AP -1 -mediated drug resistance, drug sensitivity of all four cell lines was monitored following infection with Advector and AdA -FOS. It is important to note that for the MTT assay, A2780 /CP70, KB8, and KB85 cells were infected with
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MOIs ranging from 1 to 64. A2780 cells were infected with MOIs ranging from 50 to 3200 to reflect the relative cytotoxic effect of Advector on each cell line (Fig 2C  and D ) . MOI doses were analyzed in which cellular viability was affected similarly by Advector and AdA -FOS but was greater than 75% of uninfected control cells. Following infection, the cells were treated with the IC 10 cisplatin doses of 0.1 m for A2780 or 1 m for A2780/ CP70 cells ( Fig 4A ) and colchicine doses of 3 ng /mL for KB8 and 10 ng /mL for KB85 cells for 48 hours ( Fig  4B ) . The IC 10 killing of either cisplatin or colchicine in the drug -sensitive cell lines, A2780 and KB8, was not affected by either Advector or AdA -FOS (Fig 4A and  B ) . In the drug -resistant cell lines, A2780/ CP70 and KB85, a selective effect of AdA -FOS was reproducibly observed. Whereas Advector did not alter the IC 10 killing of either cisplatin or colchicine, AdA -FOS potentiated this killing by 3-fold.
AdA -FOS specifically enhanced cisplatin -mediated cell killing
To verify the specificity of AP -1 as a therapeutic molecular target, we infected A2780/ CP70 cells with Advector, AdA -FOS, and five additional adenoviruses expressing transcription factor DNs. These five adenoviruses express DNs to the B -ZIP transcription factors VBP and C /EBP or the B-HLH -ZIP transcription factors Myc, USF and Mi. Protein with the expected molecular weight was detected after infection for all six FLAG -tagged A -ZIP and A -HLH -ZIP proteins ( Fig 5A ) . At 48 hours postinfection, cells were treated with IC 10 cisplatin and 6 days later assayed for colony formation. In the absence of cisplatin, AdA -MAX and Advector had no effect on colony formation whereas AdA -FOS and AdA -USF resulted in dramatic decreases to 15% and 30%, respectively (Fig 5B ) . To analyze the effect of adenovirus on drug sensitivity, we looked at the effect of Cancer Gene Therapy IC 10 cisplatin on colony formation in the presence of adenovirus. AdA -FOS enhanced cell killing by 3 -fold. In contrast, A2780/ CP70 killing by cisplatin was unaltered following infection with Advector, AdA -CEBP, AdA -VBP, AdA -USF, and AdA -MI. This verified the selectivity of AdA -FOS in reversing drug resistance.
AdA -FOS abolished DNA binding of the AP-1 complex in drug -resistant cells
We examined whether the effects of AdA -FOS was correlated with an inhibition of AP -1 DNA -binding activity in the drug -resistant A2780 /CP70 and KB85 cells. Nuclear extracts were prepared from A2780 /CP70 or KB85 cells infected with Advector or AdA -FOS for 4 days and then exposed to 2 m cisplatin or 10 ng/ mL colchicine for 18 hours. Nuclear proteins were isolated and bound to a 28 -bp double -stranded radiolabeled oligonucleotide containing the consensus AP -1 binding site, the TRE ( 5 0 -TGACTCA -3 0 ). AP -1 DNA -binding activity was observed in all the extracts except for the AdA -FOS infected sample. Thus, expression of A -FOS is able to abolish the AP -1 DNA -binding activity, and this property is specific to AdA -FOS (Fig 6 ) . The parental A2780 and KB8 cells do not have a detectable AP -1 gel shift activity; therefore, inhibition of the gel shift activity in these cells could not be tested. 
Cancer Gene Therapy
Discussion
Activation of the AP -1 complex occurs in both neoplastic and drug -resistance cells. 45 We show that adenoviral delivery of A -FOS, a DN that inhibits the DNA binding of the AP -1 transcriptional complex, inhibits cellular viability of the cisplatin-resistant A2780 /CP70 human ovarian cell line and multidrug -resistant KB85 epidermal carcinoma cell line, but not the parental A2780 or KB8 lines. The specificity of AdA -FOS inhibition was examined by comparing its effects with those of an empty vector control adenovirus ( Advector ) and five recombinant adenoviruses expressing DNs to other B -ZIP and B -HLH -ZIP protein families. AdA -USF, an adenovirus expressing a DN to USF, inhibited colony formation ( Fig 5 ) , consistent with the observation that USF activity is essential for cell viability. 46 However, A -USF did not enhance cisplatin -mediated cell death suggesting that A -USF is inhibiting growth through pathways distinct from the A -FOS pathways. None of the remaining four adenoviruses strongly affected colony formation, either in the presence or absence of cisplatin, indicating the specificity of the AdA -FOS effects.
It seems likely that increased killing of the drugresistant cells is due to A -FOS inhibition of AP -1 -mediated transcriptional events that are essential in drug resistance. In the A2780 /CP70 cells, high levels of transcription of ERCC1 are thought to mediate resistance, whereas in KB85 cells, high levels of mdr1 are considered essential to the mdr phenotype. Both of these promoters are associated with either activation of AP -1 or Ras. 30, 47 An analysis of ERCC1 transcript levels in A2780 /CP70 cells showed a consistent and specific reduction in ERCC1 mRNA by AdA -FOS that was not observed following infection with Advector or adenovirus expressing DNs to C /EBP, USF, MAX, VBP or MI ( data not shown ). However, we did not detect specific decreases in mdr-1 when mdr was assayed by either Northern or Western analysis, or by drug efflux studies (data not shown ). Although this strongly suggests that these cells are mediating drug resistance through a non p -gp AP -1 regulated pathway, the mechanism of selectively preventing growth of drug -resistant A2780 /CP70 and KB85 cell lines remains to be elucidated.
Several previously reported approaches have implicated AP -1 in drug resistance. Phosphorylation of c -JUN by the Jun N -terminal kinase (JNK ) is a requirement for AP -1 transactivation. Stable cell lines expressing a mutant of c -JUN that cannot be phosphorylated, have lower cisplatin killing profiles than the AP -1 inducible parental cells. 48 RAS is involved in the unregulated growth in around 30% of neoplastic cells.
11 RAS is upstream of AP -1 and is also able to produce drug resistance. 49 Inhibition of RAS by a ribozyme inhibited colon cell growth. 50 Adenoviral delivery of a single -chain antibody fragment directed against RAS enhanced radiosensitivity of tumor cells but not normal cells. 51 Our findings that AP -1 inhibits growth and increases drug susceptibility in drug -resistant A2780/ CP70 and KB85 cells is consistent with the proposal that, in drug -resistant cells, the RAS pathway is likely involved in both cell growth and drug resistance. Thus, AP -1 represents a therapeutic target with profound clinical implications. Work is under way to determine whether the response detected in these two-cell systems in reproducible over a wider array of drugresistant cell lines. Further study is necessary to understand at a molecular level signals that regulate AP -1 activity, apparently switching between the induction of apoptosis 3 and the induction of drug resistance.
